Overview

Lung Cancer Cryo-Activation as a Novel Approach to Augment Immunotherapy Efficacy (CRYOVATE)

Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
Cryo-activation involves the insertion of a cryoprobe in the tumor bed with subsequent cell necrosis and tumor antigens release. Such technique has the potential to induce immune-specific reactions influencing cancer cells outside of the ablated region. The addition of cryo-activation to immune-checkpoint blockers (ICB) in the advanced NSCLC setting could represent a synergistic therapeutic avenue in order to potentiate treatment responses
Phase:
N/A
Details
Lead Sponsor:
Centre hospitalier de l'Université de Montréal (CHUM)
Treatments:
Pembrolizumab